Search Results for "Risperdal"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Risperdal. Results 11 to 20 of 29 total matches.
See also: risperidone

In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022  (Issue 1641)
months5 11,760.30 Risperidone – Risperdal Consta 12.5, 25, 37.5, 50 mg vials 25, 37.5, or 50 mg IM q2 ...
Invega Hafyera (Janssen), a long-acting, extended-release (ER) formulation of the second-generation antipsychotic paliperidone palmitate, has been approved by the FDA for twice-yearly IM treatment of schizophrenia in adults who have been adequately treated with another injectable ER formulation of the drug (Invega Sustenna or Invega Trinza). It is the first drug to become available in the US for twice-yearly treatment of schizophrenia.
Med Lett Drugs Ther. 2022 Jan 10;64(1641):7-8 |  Show IntroductionHide Introduction

In Brief: Injectable Paliperidone Palmitate for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88 |  Show IntroductionHide Introduction

Triptorelin (Triptodur) for Central Precocious Puberty

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018  (Issue 1537)
have occurred. DRUG INTERACTIONS — Hyperprolactinemic drugs, such as phenothiazines, risperidone (Risperdal ...
The FDA has approved an extended-release intramuscular suspension formulation of the gonadotropin-releasing hormone (GnRH) agonist triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly treatment of central precocious puberty (CPP) in children ≥2 years old. Triptorelin has been available in the US for years as Trelstar for palliative treatment of advanced prostate cancer. Before the approval of Triptodur, Trelstar was used off-label for treatment of CPP.
Med Lett Drugs Ther. 2018 Jan 1;60(1537):7-8 |  Show IntroductionHide Introduction

In Brief: Three New Injectable Antipsychotic Drugs

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
Risperdal Consta (Janssen) 12.5, 25, 37.5, 50 mg vials 25, 37.5, or 50 mg IM q2 weeks8 1229.10 Rykindo ...
Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for treatment of schizophrenia in adults. Rykindo and Abilify Asimtufii are also approved for maintenance treatment of bipolar I disorder in adults. Other extended-release injectable formulations of risperidone and aripiprazole have been available in the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8   doi:10.58347/tml.2023.1692d |  Show IntroductionHide Introduction

Extended-Release Carbamazepine (Equetro) for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
Sedation, hyponatremia Trileptal divided bid 184.50 Risperidone – Risperdal Acute mania/mixed 1-6 mg once ...
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Med Lett Drugs Ther. 2005 Mar 28;47(1205):27-8 |  Show IntroductionHide Introduction

Brexpiprazole (Rexulti) for Schizophrenia and Depression

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
, 4, mg tabs; 4-8 mg/d in 1 or 2 mg/d in 1 or 25.60 Risperdal (Janssen) 1 mg/mL soln 2 doses 2 doses7 ...
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify), a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):116-8 |  Show IntroductionHide Introduction

Two Long-Acting Injectable Antipsychotics for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
, 37.5, 50 mg vials 25 mg IM q2 weeks 723.70 Risperdal Consta (Janssen) IM = intramuscular; SC ...
The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil (Aristada – Alkermes), which is given once every 4-6 weeks, and paliperidone palmitate (Invega Trinza – Janssen), which is given once every 3 months. Once-monthly injectable formulations of aripiprazole (Abilify Maintena) and paliperidone palmitate (Invega Sustenna) were approved earlier.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):152-3 |  Show IntroductionHide Introduction

Ziprasidone (Geodon) For Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
Risperidone − Risperdal (Janssen) 3 mg bid or 6 mg once daily 313.42 Ziprasidone − Geodon (Pfizer) 20 mg bid ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):51-2 |  Show IntroductionHide Introduction

Aripiprazole (Abilify) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003  (Issue 1150)
Quetiapine − Seroquel (AstraZeneca) 250 mg bid 486.00 Risperidone − Risperdal (Janssen) 4 mg once daily ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Med Lett Drugs Ther. 2003 Feb 17;45(1150):15-6 |  Show IntroductionHide Introduction

AmpliChip CYP450 Test

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005  (Issue 1215)
) aripiprazole (Abilify) phenytoin (Dilantin) haloperidol (Haldol) voriconazole (Vfend) risperidone (Risperdal ...
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Med Lett Drugs Ther. 2005 Aug 15;47(1215):71-2 |  Show IntroductionHide Introduction